Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, A Humanized Monoclonal Antibody That Targets α5β1 Integrin For The Treatment Of Both Sporadic And Familial ALS
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics Corp. (NASDAQ:KTTA) has selected a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS). The company has performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS. The humanized lead candidate is a potent inhibitor of the primary ligand fibronectin (FN), has been optimized for high affinity and has high (sub-nanomolar) specificity with contact sites directly adjacent to the FN binding site documented by cryogenic electron microscopy (cryo-EM).

November 09, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics has selected a lead candidate for its PAS-003 program, a humanized monoclonal antibody for ALS treatment. This could potentially lead to a new treatment for ALS, which currently has limited treatment options.
The selection of a lead candidate for the PAS-003 program is a significant milestone for Pasithea Therapeutics. This could potentially lead to a new treatment for ALS, a disease with limited treatment options. This news could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100